NIAID awards VaxInnate a $2.2M grant to develop dengue vaccine

04/5/2013 | Genetic Engineering & Biotechnology News

The National Institute of Allergy and Infectious Diseases awarded VaxInnate a three-year grant worth $2.2 million to develop a recombinant tetravalent dengue vaccine using the company's Toll-like receptor (TLR) platform. The TLR technology is intended to increase vaccine efficacy and immunogenicity.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Systems Test - V&V Engineer - 14000008LS
Abbott
San Jose, CA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC